Paul Sabatier University is a French university, in the Academy of Toulouse.Founded in 1229, the University of Toulouse is one of the oldest in Europe. Today’s Toulouse III was named for Paul Sabatier, winner of the 1912 Nobel prize in chemistry, when it was established on the foundations of the old university in 1969. The Université Paul Sabatier , an educational leader in France’s Midi-Pyrénées region, offers a broad array of programs in the science, technology, health, and athletics. Wikipedia.
University Paul Sabatier | Date: 2014-01-16
The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
French National Center for Scientific Research and University Paul Sabatier | Date: 2014-06-05
An object of the present invention is to provide a cheap and efficient method and device to remove ions from an electrolytic media, such as water desalination. The invention relates to a cell adapted to remove ions from an liquid electrolytic media, comprising a housing with:
University Paul Sabatier | Date: 2014-04-23
Polymen, Arkema, French National Center for Scientific Research and University Paul Sabatier | Date: 2014-03-11
A copolymer having amphiphilic blocks includes at least one first hydrophilic block, obtainable from n-butyl acrylate and hydroxyethyl methacrylate monomers, and a second hydrophobic block likely to be obtained from a methyl methacrylate monomer. The copolymer is found to be particularly advantageous for use as an additive for manufacturing a polymer filtration membrane, particularly a PVDF membrane, particularly via a phase inversion method.
French Institute of Health, Medical Research, University Paul Sabatier and French National Center for Scientific Research | Date: 2013-05-03
The present invention relates to a compound which inhibits the binding of activin B to ALK3 receptor or a compound which is an inhibitor of activin B expression or ALK3 receptor expression for use in the treatment of anemia of inflammation. The invention also relates to a method for diagnosis anemia of inflammation in a patient comprising: determining the expression level of Activin B in a sample obtained from said patient; and comparing said expression level to a threshold value.